F-15599

F-15599
Clinical data

Other names	F-15599; F15599; NLX-101; NLX101
Routes of administration	Oral
Drug class	Serotonin 5-HT_1A receptor agonist
Legal status
Legal status	Investigational
Pharmacokinetic data
Metabolism	DB16936DB16936
Identifiers
IUPAC name 3-Chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1-yl]methanone
CAS Number	635323-95-4^Y
PubChem CID	11741361
IUPHAR/BPS	3924
DrugBank	DB16936
ChemSpider	9916065^Y
UNII	83481Y1YCX
ChEMBL	ChEMBL230963
CompTox Dashboard (EPA)	DTXSID901029377
Chemical and physical data
Formula	C₁₉H₂₂ClF₂N₄O
Molar mass	395.86 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES Cc3cnc(nc3)CNCC(F)(CC2)CCN2C(=O)c(cc1Cl)ccc1F
InChI InChI=1S/C19H21ClF2N4O/c1-13-9-24-17(25-10-13)11-23-12-19(22)4-6-26(7-5-19)18(27)14-2-3-16(21)15(20)8-14/h2-3,8-10,23H,4-7,11-12H2,1H3^N Key:WAAXKNFGOFTGLP-UHFFFAOYSA-N^N
(verify)

F-15,599, also known as NLX-101, is a potent and selective 5-HT_1A receptor full agonist. In addition, it displays functional selectivity, or biased agonism, by preferentially activating postsynaptic serotonin 5-HT_1A receptors over somatodendritic serotonin 5-HT_1A autoreceptors. The drug has been investigated for potential use as a pharmaceutical drug in the treatment of conditions including depression, schizophrenia, cognitive disorders, Rett syndrome, and fragile X syndrome.